"During the second half of the financial year, the Company will be focused on:
Continuing detailed supplementary analyses of samples from the Phase 2 HIV-1 trial seeking to furthercharacterise the clinical efficacy of BIT225.
Ongoing discussions and sharing of data from the HIV-1 Phase 2 clinical trial with potential partners.
Undertaking additional in vitro cell-based preclinical testing of compounds for the HBV program, includingscreening of newly designed and synthesized compounds for potential anti-HBV activity.
Continued testing of Biotron compounds for activity against other key commercially relevant virus targets."
- Forums
- ASX - By Stock
- Ann: Half Yearly Report and Accounts
"During the second half of the financial year, the Company will...
-
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add BIT (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M |
Open | High | Low | Value | Volume |
1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 1050263 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 512798 | 0.019 |
10 | 1774771 | 0.018 |
8 | 927388 | 0.017 |
12 | 3258350 | 0.016 |
7 | 865000 | 0.015 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 1000263 | 4 |
0.021 | 555000 | 2 |
0.022 | 997769 | 4 |
0.023 | 1100772 | 2 |
0.024 | 153949 | 2 |
Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |